Publication: Imidazole-modified deferasirox encapsulated polymeric micelles as pH-responsive iron-chelating nanocarrier for cancer chemotherapy
Issued Date
2017-01-01
Resource Type
ISSN
20462069
Other identifier(s)
2-s2.0-85013102445
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
RSC Advances. Vol.7, No.18 (2017), 11158-11169
Suggested Citation
Man Theerasilp, Punlop Chalermpanapun, Kanyawan Ponlamuangdee, Dusita Sukvanitvichai, Norased Nasongkla Imidazole-modified deferasirox encapsulated polymeric micelles as pH-responsive iron-chelating nanocarrier for cancer chemotherapy. RSC Advances. Vol.7, No.18 (2017), 11158-11169. doi:10.1039/c6ra26669j Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/42213
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Imidazole-modified deferasirox encapsulated polymeric micelles as pH-responsive iron-chelating nanocarrier for cancer chemotherapy
Other Contributor(s)
Abstract
© The Royal Society of Chemistry. Deferasirox (Def) is an iron-chelating drug used to reduce iron overload in β-thalassemia patients. After the discovery of its tumor growth inhibition, this drug gained tremendous attention in cancer chemotherapy. Herein, deferasirox and its derivatives including methoxy (mDef) and imidazole-modified (iDef) deferasirox were encapsulated in polymeric micelles. Results showed that the release of deferasirox from polymeric micelles was faster at pH 7.4 (physiological condition) than at pH 4.5 (lysosomal condition). However, the release of mDef was pH-independent where both Def and mDef are not suitable for in vivo applications. Therefore, iDef was synthesized to change the pKa from 3.7 (carbonyl group of Def) to 6.8 (imidazole group of iDef) without interfering the iron-chelating efficacy. Interestingly, the release rate of imidazole-modified deferasirox was conversed from that of deferasirox where it exhibited slow release at physiological condition and faster release at the lysosomal condition. This release profile showed a pH-response and an ON-OFF release behavior where iDef is encapsulated in micelles during systemic circulation and released inside cancer cells after intracellular endosomes/lysosome. Cytotoxicity of deferasirox and modified deferasirox were also investigated, and it was found that the IC50 against PC-3 and HepG2 cell lines were in the range of micromolar to submicromolar. Flow cytometry analysis confirmed a decrease in the amount of iron inside lysosome when cells were treated by iDef-loaded micelles. Therefore, iDef-loaded micelles have potential application in cancer treatment as a pH-responsive iron-chelating nanocarrier.